results from the keynote-716: pembrolizumab versus placebo after complete resection of high-risk...
Published 3 years ago • 87 plays • Length 3:46Download video MP4
Download video MP3
Similar videos
-
2:18
keynote-716: longer follow up supports pembrolizumab use in stage iib/iic melanoma
-
2:19
#esmo21 highlights on pembrolizumab in fully resected high-risk stage ii melanoma: keynote-716 study
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
1:08
keynote-716: safety profile and results of pembrolizumab for melanoma
-
0:43
keynote-716: adjuvant pembrolizumab for high-risk melanoma
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
0:48
final analysis of distant metastasis-free survival in the keynote-716 study
-
30:30
how to understand the standard of care for stage ii melanoma patients
-
4:27
key updates in immunotherapies for melanoma
-
9:31
new options for immunotherapy trials
-
0:33
keynote-716: pembrolizumab in stage 2b/2c cutaneous melanoma
-
10:36
results of keynote-054; melanoma patients treated with pembrolizumab
-
2:31
pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma
-
9:16
keynote-522: pembro ct vs placebo ct neoadjuvant followed adjuvant pembro vs placebo in tnbc
-
6:52
expert report on novel data in (neo)adjuvant treatment of melanoma from asco 2022
-
9:40
reducing recurrence of advanced melanoma with pembrolizumab
-
1:23
3-year update shows continued efficacy of pembrolizumab for melanoma
-
8:35
long-term results for immunotherapy in melanoma
-
8:21
i did not expect that. metastatic melanoma.
-
1:08
the decisiondx®-melanoma test complements current melanoma staging
-
3:03
what's the best option in the treatment of melanoma?